Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- Cancer centers scramble amid shortage of ‘essential drug’ used to treat childrenon October 17, 2019 at 10:56 pm
Vincristine is a standard treatment, primarily for children with leukemia, lymphoma, bone and brain cancers. Around two weeks ago, drugmaker Pfizer faced production problems. The other maker of ...
- Children's cancer treatment drug shortage could impact your petson October 17, 2019 at 8:06 pm
The Mayo Clinic said the chemotherapy drug works by stopping the growth of cancer cells. It's used to treat a common form of childhood leukemia and other cancers in children and adults. The American ...
- Shortage of vital children’s cancer drug stirs fear and outrageon October 17, 2019 at 12:38 pm
But it is a very fragile (supply) system. Without vincristine, we’d see a direct effect on a significant number of children.” On Instagram and other social media platforms, Veronica Crowfoot of Lehi, ...
- CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivityon October 17, 2019 at 3:39 am
All prices are NET prices. VAT will be added later in the checkout. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
- Pediatric cancer community rattled by shortage of staple drugon October 16, 2019 at 8:53 am
A shortage of a cancer drug in the pediatric oncology community reportedly has doctors ... for their younger patients who are facing several types of cancer, including leukemia and brain tumors. But ...
- Parents, doctors alarmed that cancer drug for children in short supplyon October 15, 2019 at 4:24 pm
“It scares me obviously,” said Nicole Starace, 45, of Hauppauge, whose 6-year-old son Ryan has leukemia and uses the drug, vincristine. “It’s something that is part of his treatment that’s keeping him ...
- Seattle Children’s opens a ‘cure factory’ to explore treatments for childhood cancer and other diseaseson October 15, 2019 at 4:00 pm
(Seattle Children’s Photo) Maryn Sage remembers the words she heard on the day she learned that her 16-year-old son, Jedd Feliciano, was cancer-free. “His marrow’s clean,” the doctor told her over the ...
- Childhood leukemia limited Stafford's Harding twins to golf. Today, they'll tee off in the state championship.on October 15, 2019 at 1:15 pm
Two separate bouts with T-cell acute lymphoblastic leukemia—culminating with bone marrow transplants in 2010—left the ... The medical staff at Inova advised the Hardings to consider Duke Children’s ...
- Faced With a Drug Shortfall, Doctors Scramble to Treat Children With Canceron October 14, 2019 at 3:54 pm
“You either have to skip a dose or give a lower dose — or beg, borrow or plead.” Vincristine is one of the drugs used to manage acute lymphoblastic leukemia, the most common childhood cancer.
- CAR T-Cell Therapy Yields Swift QoL Boost in Childhood ALLon October 14, 2019 at 12:06 pm
Chimeric antigen receptor (CAR) T-cell therapy led to quick gains in quality of life (QoL) for children and young adults with relapsed or refractory acute leukemia, a patient-reported outcomes ...
via Bing News